Cite
Integrative analyses identify CD73 as a prognostic biomarker and immunotherapeutic target in intrahepatic cholangiocarcinoma.
MLA
Sun, Bao-Ye, et al. “Integrative Analyses Identify CD73 as a Prognostic Biomarker and Immunotherapeutic Target in Intrahepatic Cholangiocarcinoma.” World Journal of Surgical Oncology, vol. 21, no. 1, Mar. 2023, pp. 1–16. EBSCOhost, https://doi.org/10.1186/s12957-023-02970-6.
APA
Sun, B.-Y., Yang, Z.-F., Wang, Z.-T., Liu, G., Zhou, C., Zhou, J., Fan, J., Gan, W., Yi, Y., & Qiu, S.-J. (2023). Integrative analyses identify CD73 as a prognostic biomarker and immunotherapeutic target in intrahepatic cholangiocarcinoma. World Journal of Surgical Oncology, 21(1), 1–16. https://doi.org/10.1186/s12957-023-02970-6
Chicago
Sun, Bao-Ye, Zhang-Fu Yang, Zhu-Tao Wang, Gao Liu, Cheng Zhou, Jian Zhou, Jia Fan, Wei Gan, Yong Yi, and Shuang-Jian Qiu. 2023. “Integrative Analyses Identify CD73 as a Prognostic Biomarker and Immunotherapeutic Target in Intrahepatic Cholangiocarcinoma.” World Journal of Surgical Oncology 21 (1): 1–16. doi:10.1186/s12957-023-02970-6.